Abeona Therapeutics Inc. (ABEO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Abeona Therapeutics Inc. (ABEO) closed at USD 4.36 on 2026-10-14, a change of -17.4 % over the past year, with a market capitalization of USD 265.91M.

Abeona Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Abeona Therapeutics Inc. key figures

Previous close

USD 4.36 (2026-10-14)

1-year change

-17.4 %

Market cap

USD 265.91M

Enterprise value

USD 138.95M

P/E ratio (trailing)

-3.84

P/E ratio (forward)

-22.41

EPS (trailing)

-1.21

EPS (forward)

-0.21

PEG ratio

n/a

Price to book

2.08

Revenue growth

2,745 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

12.15

Employees

226

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Abeona Therapeutics Inc. and compare it with other stocks.